Reducing relapse through maintenance steroid treatment can decrease the cancer risk in patients with IgG4-sclerosing cholangitis: Based on a Japanese nationwide study
Kensuke Kubota,Terumi Kamisawa,Takahiro Nakazawa,Atsushi Tanaka,Itaru Naitoh,Yusuke Kurita,Hajime Takikawa,Michiaki Unno,Shigeyuki Kawa,Atsushi Masamune,Seiji Nakamura,Kazuichi Okazaki,Collaborators,Keisuke Furumatsu,Shigeaki Sawai,Takuma Goto,Toshikatsu Okumura,Daisuke Suzuki,Masayuki Otsuka,Ikuhiro Kobori,Masaya Tamano,Mitsuhito Koizumi,Yoichi Hiasa,Naoto Kawabe,Yoshiki Hirooka,Satoshi Yamamoto,Yukio Asano,Kazuo Inui,Akihiko Horiguchi,Hiroyuki Watanabe,Daishu Toya,Katsuko Hatayama,Toshiharu Ueki,Norikatsu Kinoshita,Mitsuru Sugimoto,Hiromasa Ohira,Tsuyoshi Mukai,Eiichi Tomita,Keisuke Iwata,Shogo Shimizu,Jun Suetsugu,Masahito Shimizu,Keiji Tsuji,Ryoko Ishida,Masanori Ito,Ryutaro Furukawa,Naoya Sakamoto,Masahiro Araki,Satoshi Tanno,Yasunari Sakamoto,Tetsuhide Ito,Satoshi Takai,Shinichi Ikeya,Takanori Yamada,Norihiko Kudara,Akinori Shimizu,Keiji Hanada,Yasunori Ichiki,Hideki Kitada,Michio Hifumi,Hiroyuki Kimura,Masayuki Kurosaki,Namiki Izumi,Hajime Sumi,Jun-Ichi Haruta,Katsumi Hayashi,Ryo Harada,Masafumi Inoue,Shinichiro Nakamura,Tetsuya Ito,Ko Tomishima,Hiroyuki Isayama,Kyoko Oura,Tsutomu Masaki,Naoto Shimokawahara,Shirou Tanoue,Kousei Maemura,Akio Ido,Ichiro Mizushima,Mitsuhiro Kawano,Katsunori Yoshida,Makoto Naganuma,Miki Murata,Akiyoshi Nishio,Yuji Fujita,Takuma Teratani,Shohei Matsubara,Hironao Tamai,Yuu Yoshida,Ryousaku Azemoto,Ken Kamata,Tomohiro Watanabe,Takahiro Kurosu,Wasaburou Koizumi,Jun Fujita,Hideyuki Seki,Yasuhiro Ueda,Takumi Fukumoto,Takuhiro Kousaki,Kazushige Uchida,Toshimasa Ochiai,Takeshi Kawasaki,Motohiko Tanaka,Etsuji Ishida,Kenji Notohara,Hideaki Mori,Toshiyuki Mori,Hideaki Kawabata,Masatoshi Miyata,Junichi Sakagami,Yoshito Itoh,Masahiro Shiokawa,Hiroshi Seno,Noriko Watanabe,Hiromi Kataoka,Toshinori Aoki,Mitsuhiro Fujishiro,Toru Niihara,Hiroto Nishimata,Akira Mitoro,Hitoshi Yoshiji,Motoyuki Yoshida,Masafumi Ikeda,Kengo Tomita,Ryota Hokari,Kenji Hayasaka,Yuji Amano,Kazuhiko Shioji,Kazunao Hayashi,Shuji Terai,Michiko Nakajima,Junya Yamahana,Ryusuke Matsumoto,Hideaki Kikuchi,Akira Kanamori,Seiki Kiriyama,Shinichi Iwatsu,Yuji Kato,Shigeru Horiguchi,Takahito Yagi,Hiroyuki Okada,Kazuyoshi Ohkawa,Motohiro Hirao,Naoki Hiramatsu,Noriko Oza,Haruo Imamura,Takeshi Baba,Shigeru Nakano,Tetsuya Shinobi,Shomei Ryozawa,Masayo Motoya,Hiroshi Nakase,Noboru Kinoshita,Kei Ito,Tatsuya Miyake,Naruaki Kohge,Hiroshi Tobita,Satoru Joshita,Takeji Umemura,Shinya Kawaguchi,Kazuya Ohno,Koichi Sonobe,Akihiko Satoh,Tooru Shimosegawa,Fumihiko Miura,Minami Yagi,Keiji Sano,Toshifumi Kin,Akio Katanuma,Kazuhiko Koike,Shin Miura,Youhei Kawashima,Tatehiro Kagawa,Seishin Azuma,Mamoru Watanabe,Mitsuyoshi Honjyo,Takao Itoi,Akira Honda,Katsumasa Kobayashi,Toru Asano,Suguru Mizuno,Takayoshi Nishino,Hideaki Taniguchi,Kazuto Tajiri,Ichiro Yasuda,Yoshiya Tanaka,Shinji Oe,Masaru Harada,Masanao Kurata,Mituharu Fukasawa,Nobuyuki Enomoto,Yuki Kawaji,Masayuki Kitano,Yuko Nishise,Hidetoshi Hirakawa,Tetsuya Ishizawa,Yoshiyuki Ueno,Miyuki Kaino,Yuko Fujimoto,Isao Sakaida
DOI: https://doi.org/10.1111/jgh.16066
Abstract:Objective: IgG4-related sclerosing cholangitis (IgG4-SC) is recognized as a benign steroid-responsive disease; however, little is known about the risk of development of cancer in patients with IgG4-SC and about how to counter this risk. Design: We conducted a retrospective review of the data of 924 patients with IgG4-SC selected from a Japanese nationwide survey. The incidence, type of malignancy, and risk of malignancy in these patients were examined. Then, the standardized incidence ratio (SIR) of cancer in patients with IgG4-SC was calculated. Results: Relapse was recognized in 19.7% (182/924) of patients, and cancer development was noted in 15% (139/924) of patients. Multivariate analysis identified only relapse as an independent risk factor for the development of cancer. In most of these patients with pancreato-biliary cancer, the cancer developed within 8 years after the diagnosis of IgG4-SC. The SIR for cancer after the diagnosis of IgG4-SC was 12.68 (95% confidence interval [CI] 6.89-8.79). The SIRs of cancers involving the biliary system and pancreas were 27.35 and 18.43, respectively. The cumulative survival rate was significantly better in the group that received maintenance steroid treatment (MST) than in the group that did not; thus, MST influenced the prognosis of these patients. Conclusion: Among the cancers, the risk of pancreatic and biliary cancers is the highest in these patients. Because of the elevated cancer risk, surveillance after the diagnosis and management to prevent relapse are important in patients with IgG4-SC to reduce the risk of development of cancer.